FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164112814> ?p ?o ?g. }

• W3164112814 endingPage "6164" @default.
• W3164112814 startingPage "6157" @default.
• W3164112814 abstract "The current recommended therapy of obstetric antiphospholipid syndrome (APS) is a long-term anticoagulant therapy that affects the final event, namely, when the thrombosis has already occurred. Unfortunately, this schedule is not always effective and fails despite the correct risk stratification and an adequate adjusted dose.From 2013 to 2020 we observed 217 women with antiphospholipid antibodies and obstetric morbidities who were treated with conventional treatment protocol (aspirin low doses ± LMWH). Among them 150 (69.1%) successfully completed pregnancy with delivery and live birth on the background of LMWH and aspirin therapy and in 67 (30.9%) women despite a traditional therapy regimen, obstetric complications were noted. Later, 56 of these 67 women became pregnant again and were offered traditional therapy plus hydroxychloroquine. Fifteen women refused HCQ treatment due to possible potential side effects. The final cohort consisted of 41 women with positive antiphospholipid antibodies and obstetric and thrombotic complications who received LMWH, aspirin low doses and HCQ at a dose of 200-400mg per day from the beginning of pregnancy.Forty-one aPL women treated with HCQ after failed previous anticoagulant therapy had live births in 32 cases (78%). Adding of HCQ to the combination of LMWH and LDA showed good overall obstetric results and increased the number of live births in another 32 women. So, a total of 182 (83.8%) of initial 217 aPL-women ended their pregnancies with live birth after adding the HCQ to the traditional therapy with LMWH and low doses of aspirin.In 20-30% of cases the live birth despite anticoagulation cannot be achieved. Perhaps APS is not just anticoagulation. The study of pathophysiological mechanisms suggests that some patients will benefit from other therapy (in addition to anticoagulant). Therapy that affects the early effects of aPL on target cells (monocytes, endothelial cells, etc.) or before binding to receptors-this therapy will be preferable and potentially less harmful than the officially accepted one to date. From this point of view, HCQ looks promising and can be used as an alternative candidate for women with refractory obstetric antiphospholipid syndrome. Adding HCQ should be considered in some selected patients with failed pregnancy after treatment with anticoagulants." @default.
• W3164112814 created "2021-06-07" @default.
• W3164112814 creator A5001878328 @default.
• W3164112814 creator A5005021934 @default.
• W3164112814 creator A5005303108 @default.
• W3164112814 creator A5007544098 @default.
• W3164112814 creator A5010998467 @default.
• W3164112814 creator A5012921884 @default.
• W3164112814 creator A5019743703 @default.
• W3164112814 creator A5030761240 @default.
• W3164112814 creator A5030958882 @default.
• W3164112814 creator A5036054589 @default.
• W3164112814 creator A5036715797 @default.
• W3164112814 creator A5038863992 @default.
• W3164112814 creator A5044889497 @default.
• W3164112814 creator A5054201223 @default.
• W3164112814 creator A5069257295 @default.
• W3164112814 creator A5076258346 @default.
• W3164112814 creator A5079447134 @default.
• W3164112814 creator A5081001290 @default.
• W3164112814 creator A5082017722 @default.
• W3164112814 creator A5085178926 @default.
• W3164112814 creator A5089575976 @default.
• W3164112814 date "2021-05-27" @default.
• W3164112814 modified "2023-09-29" @default.
• W3164112814 title "Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases" @default.
• W3164112814 cites W1510159827 @default.
• W3164112814 cites W1553601962 @default.
• W3164112814 cites W1874283454 @default.
• W3164112814 cites W1970992598 @default.
• W3164112814 cites W1975166936 @default.
• W3164112814 cites W1991721757 @default.
• W3164112814 cites W1999590302 @default.
• W3164112814 cites W2034890148 @default.
• W3164112814 cites W2047849140 @default.
• W3164112814 cites W2049415615 @default.
• W3164112814 cites W2054330426 @default.
• W3164112814 cites W2070013537 @default.
• W3164112814 cites W2089268757 @default.
• W3164112814 cites W2093796906 @default.
• W3164112814 cites W2097402525 @default.
• W3164112814 cites W2098256888 @default.
• W3164112814 cites W2140537006 @default.
• W3164112814 cites W2154374203 @default.
• W3164112814 cites W2323544259 @default.
• W3164112814 cites W2494545820 @default.
• W3164112814 cites W2626026527 @default.
• W3164112814 cites W2752830593 @default.
• W3164112814 cites W2790243308 @default.
• W3164112814 cites W2811244610 @default.
• W3164112814 cites W2898017527 @default.
• W3164112814 cites W2914608321 @default.
• W3164112814 cites W2970428872 @default.
• W3164112814 cites W2972886361 @default.
• W3164112814 cites W3043038558 @default.
• W3164112814 cites W3112053577 @default.
• W3164112814 cites W3124912006 @default.
• W3164112814 cites W4251651167 @default.
• W3164112814 doi "https://doi.org/10.1080/14767058.2021.1908992" @default.
• W3164112814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34044735" @default.
• W3164112814 hasPublicationYear "2021" @default.
• W3164112814 type Work @default.
• W3164112814 sameAs 3164112814 @default.
• W3164112814 citedByCount "4" @default.
• W3164112814 countsByYear W31641128142022 @default.
• W3164112814 countsByYear W31641128142023 @default.
• W3164112814 crossrefType "journal-article" @default.
• W3164112814 hasAuthorship W3164112814A5001878328 @default.
• W3164112814 hasAuthorship W3164112814A5005021934 @default.
• W3164112814 hasAuthorship W3164112814A5005303108 @default.
• W3164112814 hasAuthorship W3164112814A5007544098 @default.
• W3164112814 hasAuthorship W3164112814A5010998467 @default.
• W3164112814 hasAuthorship W3164112814A5012921884 @default.
• W3164112814 hasAuthorship W3164112814A5019743703 @default.
• W3164112814 hasAuthorship W3164112814A5030761240 @default.
• W3164112814 hasAuthorship W3164112814A5030958882 @default.
• W3164112814 hasAuthorship W3164112814A5036054589 @default.
• W3164112814 hasAuthorship W3164112814A5036715797 @default.
• W3164112814 hasAuthorship W3164112814A5038863992 @default.
• W3164112814 hasAuthorship W3164112814A5044889497 @default.
• W3164112814 hasAuthorship W3164112814A5054201223 @default.
• W3164112814 hasAuthorship W3164112814A5069257295 @default.
• W3164112814 hasAuthorship W3164112814A5076258346 @default.
• W3164112814 hasAuthorship W3164112814A5079447134 @default.
• W3164112814 hasAuthorship W3164112814A5081001290 @default.
• W3164112814 hasAuthorship W3164112814A5082017722 @default.
• W3164112814 hasAuthorship W3164112814A5085178926 @default.
• W3164112814 hasAuthorship W3164112814A5089575976 @default.
• W3164112814 hasConcept C126322002 @default.
• W3164112814 hasConcept C131872663 @default.
• W3164112814 hasConcept C141071460 @default.
• W3164112814 hasConcept C187212893 @default.
• W3164112814 hasConcept C2776874634 @default.
• W3164112814 hasConcept C2777628954 @default.
• W3164112814 hasConcept C2778279030 @default.
• W3164112814 hasConcept C2779123688 @default.
• W3164112814 hasConcept C2779134260 @default.
• W3164112814 hasConcept C2779234561 @default.

• next